ES2524645B1 - Oral formulation for the treatment of cardiovascular diseases - Google Patents
Oral formulation for the treatment of cardiovascular diseases Download PDFInfo
- Publication number
- ES2524645B1 ES2524645B1 ES201330841A ES201330841A ES2524645B1 ES 2524645 B1 ES2524645 B1 ES 2524645B1 ES 201330841 A ES201330841 A ES 201330841A ES 201330841 A ES201330841 A ES 201330841A ES 2524645 B1 ES2524645 B1 ES 2524645B1
- Authority
- ES
- Spain
- Prior art keywords
- treatment
- cardiovascular diseases
- oral formulation
- statin
- acetylsalicylic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención se refiere al uso de una composición farmacéutica que incluye un inhibidor de la HMG-CoA reductasa, en particular, una estatina y ácido acetilsalicílico de manera que se minimiza la interacción del ácido acetilsalicílico con la estatina, para la prevención o el tratamiento de enfermedades cardiovasculares.The present invention relates to the use of a pharmaceutical composition that includes an HMG-CoA reductase inhibitor, in particular, a statin and acetylsalicylic acid so that the interaction of acetylsalicylic acid with the statin is minimized, for the prevention or treatment of cardiovascular diseases.
Description
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES201330841A ES2524645B1 (en) | 2013-06-06 | 2013-06-06 | Oral formulation for the treatment of cardiovascular diseases |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES201330841A ES2524645B1 (en) | 2013-06-06 | 2013-06-06 | Oral formulation for the treatment of cardiovascular diseases |
Publications (2)
Publication Number | Publication Date |
---|---|
ES2524645A1 ES2524645A1 (en) | 2014-12-10 |
ES2524645B1 true ES2524645B1 (en) | 2015-12-02 |
Family
ID=52004086
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES201330841A Active ES2524645B1 (en) | 2013-06-06 | 2013-06-06 | Oral formulation for the treatment of cardiovascular diseases |
Country Status (1)
Country | Link |
---|---|
ES (1) | ES2524645B1 (en) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6669955B2 (en) * | 2001-08-28 | 2003-12-30 | Longwood Pharmaceutical Research, Inc. | Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin |
TR201005325A2 (en) * | 2010-06-30 | 2012-01-23 | Bi̇lgi̇ç Mahmut | Pharmaceutical formulations containing atorvastatin and aspirin |
KR20120068277A (en) * | 2010-12-17 | 2012-06-27 | 한미사이언스 주식회사 | PHARMACEUTICAL COMPOSITE FORMULATION COMPRISING HMG-CoA REDUCTASE INHIBITOR AND ASPIRIN |
KR101298788B1 (en) * | 2011-03-15 | 2013-08-22 | 보령제약 주식회사 | A combined formulation with improved stability |
-
2013
- 2013-06-06 ES ES201330841A patent/ES2524645B1/en active Active
Also Published As
Publication number | Publication date |
---|---|
ES2524645A1 (en) | 2014-12-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2023000767A1 (en) | Methods to reduce the risk of cardiovascular events in a subject. | |
NI202100009A (en) | METHODS TO REDUCE THE NEED FOR REVASCU | |
ES2487271T3 (en) | DPP-IV inhibitor solid dosage formulations | |
SV2018005621A (en) | INHIBITOR OF MUTED DEHYDROGENASE ISOCITRATE IDH1 R132H | |
CL2015002253A1 (en) | Pharmaceutical compositions for the treatment of helicobacter pylori. | |
ECSP15050273A (en) | ORAL FORMULATION FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | |
CL2014000606A1 (en) | Pharmaceutical combination comprising the compound 2- {2 - [(2s) -2-methyl-2,3-dihydro-1h-indol-1-yl] -2-oxoethyl} -6- (morpholin-4-yl) pyrimidin -4- (3h) -one and at least one inhibitor of the mapk pathway; pharmaceutical composition; pharmaceutical kit; its use in the treatment of cancer. | |
ES2598753T3 (en) | Pharmaceutical composition for the treatment of calcified tendinitis and / or calcified bursitis | |
UY34455A (en) | COMPLEX ORAL FORMULATION THAT INCLUDES OMEGA 3 FATTY ACID AND INHIBITOR OF THE HMG-COA REDUCED WITH IMPROVED STABILITY | |
CL2016000179A1 (en) | Combination formulation containing extended-release metformin and immediate-release hmg-coa reductase inhibitor. | |
CO2019007671A2 (en) | A pharmaceutical composition comprising an oxazine derivative and its use in the treatment or prevention of Alzheimer's disease | |
ES2524645B1 (en) | Oral formulation for the treatment of cardiovascular diseases | |
UY35445A (en) | LIPOEQUILIBRATED LONG CHAIN TESTOSTERONE ESTERS FOR ORAL ADMINISTRATION | |
ES2422877B1 (en) | COMBINATION AND COMPOSITION FOR OBESITY TREATMENT | |
CO7170180A2 (en) | Injectable pharmaceutical composition of dexketoprofen and tramadol | |
ES2536842T3 (en) | Pharmaceutical composition for cancer treatment | |
ES2643369T3 (en) | Modified-release oral pharmaceutical formulation containing gliclazide | |
ES2533758B1 (en) | Composition comprising albumin for use in the treatment of decompensated cirrhosis | |
UA111358C2 (en) | Drug in form of tablets or hard capsules exhibiting sedative and hypnotic effects | |
TH126521A (en) | A pharmaceutical formulation in a two-layer tablet formulation that includes: HMG-COA Reductase Inhibitor and Urbesar Tan | |
CL2010000899A1 (en) | N1-benzyl-n8-hydroxy octanediamide; pharmaceutical composition comprising said compound; pharmaceutical combination comprising said compound; and its use in the treatment of tumors (divisional application 1247-04). |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 2524645 Country of ref document: ES Kind code of ref document: B1 Effective date: 20151202 |